Research graph
References from Chimeric Antigen Receptor T Cell Therapy for Glioblastoma: Clinical Advances and Emerging Strategies. Local targets link to admitted publications; unresolved targets remain external evidence.
Glioblastoma and other primary brain malignancies in adults: a review
10.1001/jama.2023.0023 · 2023 · External reference
20 years of the Stupp protocol: confronting stagnation in glioblastoma therapy
10.1016/s1470-2045(25)00705-3 · 2026 · External reference
Car t cells and t-cell therapies for cancer: a translational science review
10.1001/jama.2024.19462 · 2024 · External reference
CAR-T cells in solid tumors: challenges and breakthroughs
2025 · External reference
Chimeric antigen receptor T-cell immunotherapy for glioblastoma: practical insights for neurosurgeons
10.3171/2018.2.focus17788 · 2018 · External reference
Immunotherapy for glioblastoma: adoptive t-cell strategies
10.1158/1078-0432.ccr-18-1625 · 2019 · External reference
Altered cancer metabolism and implications for next-generation CAR T-cell therapies
10.1016/j.pharmthera.2024.108667 · 2024 · External reference
Tandem chimeric antigen receptor (Car) T cells targeting EGFRvIII and IL-13Rα2 are effective against heterogeneous glioblastoma
2023 · External reference
Clinical progress in the development of CAR T cells to treat malignant glioma
10.1007/s11060-024-04909-7 · 2025 · External reference
Commentary: chimeric antigen receptor t-cell therapy: updates in glioblastoma treatment
10.1093/neuros/nyab099 · 2021 · External reference
Interleukin-13 receptor alpha chain: a novel tumor-associated transmembrane protein in primary explants of human malignant gliomas
2000 · External reference
Bioactivity and safety of il13rα2-redirected chimeric antigen receptor cd8+ t cells in patients with recurrent glioblastoma
10.1158/1078-0432.ccr-15-0428 · 2015 · External reference
Regression of glioblastoma after chimeric antigen receptor t-cell therapy
10.1056/nejmoa1610497 · 2016 · External reference
Her2-specific chimeric antigen receptor-modified virus-specific t cells for progressive glioblastoma: a phase 1 dose-escalation trial
10.1001/jamaoncol.2017.0184 · 2017 · External reference
EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss
10.1158/1078-0432.ccr-13-0709 · 2014 · External reference
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma
10.1126/scitranslmed.aaa0984 · 2017 · External reference
First-in-human trial of epha2-redirected car t-cells in patients with recurrent glioblastoma: a preliminary report of three cases at the starting dose
2021 · External reference
CAR-T cell therapy for the treatment of adult high-grade gliomas
10.1038/s41698-024-00753-0 · 2024 · External reference
Administration of B7-H3 targeted chimeric antigen receptor-T cells induce regression of glioblastoma
10.1038/s41392-021-00505-7 · 2021 · External reference
Safety and antitumor activity of GD2-Specific 4SCAR-T cells in patients with glioblastoma
10.1186/s12943-022-01711-9 · 2023 · External reference
A phase 1 study of B7H3 CAR-T cells administered intracranially in recurrent glioblastoma
10.1200/jco.2025.43.16_suppl.2018 · 2025 · External reference
CAR T cells for brain tumors: lessons learned and road ahead
10.1111/imr.12773 · 2019 · External reference
Intrathecal bivalent CAR T cells targeting EGFR and IL13Rα2 in recurrent glioblastoma: phase 1 trial interim results
10.1038/s41591-024-02893-z · 2024 · External reference
Intracerebroventricular bivalent CAR T cells targeting EGFR and IL-13Rα2 in recurrent glioblastoma: a phase 1 trial
10.1038/s41591-025-03745-0 · 2025 · External reference
Bispecific antibodies engage T cells for antitumor immunotherapy
10.1517/14712598.2011.572874 · 2011 · External reference
CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity
10.1038/s41587-019-0192-1 · 2019 · External reference
Intraventricular carv3-team-e t cells in recurrent glioblastoma
10.1056/nejmoa2314390 · 2024 · External reference
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma
10.1126/scitranslmed.abe7378 · 2021 · External reference
The development and potent antitumor efficacy of CD44/CD133 dual-targeting IL7Rα-armored CAR-T cells against glioblastoma
10.1016/j.canlet.2025.217541 · 2025 · External reference
Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors
10.1158/0008-5472.can-08-3886 · 2009 · External reference
CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment
10.1136/jitc-2021-003289 · 2022 · External reference
Targeting TGFβ docking receptor glycoprotein A repetitions predominant (Garp) via novel chimeric antigen receptor (Car)-T cell platform to treat glioblastoma
10.1093/neuonc/noaf195 · 2025 · External reference
Armored bicistronic CAR T cells with dominant-negative TGF-β receptor II to overcome resistance in glioblastoma
10.1016/j.ymthe.2024.07.020 · 2024 · External reference
Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers
10.1038/s41586-024-08261-8 · 2025 · External reference
EXTH-46. IL-15 armored glypican-3 chimeric antigen receptor T cells exhibit antitumor in vitro and in murine models of glioblastoma
10.1093/neuonc/noaf201.1380 · 2025 · External reference
From concept to cure: the evolution of CAR-T cell therapy
10.1016/j.ymthe.2025.03.005 · 2025 · External reference
Oncolytic viruses in cancer treatment: a review
10.1001/jamaoncol.2016.2064 · 2017 · External reference
Immunobiology and immune therapy
2016 · External reference
Immunological correlates from phase I study of CARv3-TEAM-E in patients with recurrent glioblastoma (Gbm): INCIPIENT trial
2025 · External reference
269 humanized anti-CAR antibodies affect durable response to GD2-CAR T-cells in diffuse midline glioma
2025 · External reference
